Catalyst
Slingshot members are tracking this event:
Mast's EPIC Phase 3 Data for Vepoloxamer in Patients with Sickle Cell Disease Expected Mid Year
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
MSTX |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2016
Occurred Source:
http://masttherapeutics.com/investors/news/?releaseid=2204897
Related Projects
Related Keywords
Sickle Cell Disease, Vepoloxamer, Phase 3 Epic Trial